Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 14 years of Total Non-Current Liabilities data on file, last reported at $345.6 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 191.03% year-over-year to $345.6 million in Q1 2026; TTM through Mar 2026 was $345.6 million, a 191.03% increase from a year earlier, with the FY2025 full-year figure at $346.6 million, up 192.28% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $345.6 million, roughly flat from $346.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for MDGL reached as high as $346.6 million in Q4 2025 and fell as low as $283000.0 in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $136.1 million across 5 years, with a median of $117.2 million in 2024.
• Across the five-year window, Total Non-Current Liabilities dropped 26.87% in 2022 and jumped 29569.61% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $49.3 million in 2022, then jumped by 136.7% to $116.7 million in 2023, then gained by 1.65% to $118.6 million in 2024, then soared by 192.28% to $346.6 million in 2025, then decreased by 0.29% to $345.6 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $345.6 million in Q1 2026, $346.6 million in Q4 2025, and $345.3 million in Q3 2025.